Physician profile
Manijeh Contractor
NPI 1326224528
$3,366.51
in general payments reported to CMS, 2019-2025
21 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $62.57 · 2021: $352 · 2022: $232 · 2023: $654 · 2024: $901 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165 · Education: $23.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.19 |
| Education | $23.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $406.54 | 2019-2024 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $356.94 | 2024-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $348.44 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $275.35 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Apellis Pharmaceuticals, INC. | $231.68 | 2023-2024 | Syfovre |
| Genentech USA, INC. | $225.42 | 2019-2024 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $213.77 | 2021-2024 | Acthar |
| Alcon Vision LLC | $185.23 | 2021-2025 | Tryptyr, Rocklatan |
| Biotissue Holdings INC. | $167.81 | 2021-2025 | |
| Abbvie INC. | $141.75 | 2024-2025 | |
| Horizon Therapeutics Plc | $122.88 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $121.60 | 2021 | |
| Mallinckrodt Enterprises LLC | $121.33 | 2019 | |
| Genentech, INC. | $115.52 | 2024 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $104.13 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $61.83 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $54.83 | 2024-2025 | Iheezo, Triesence |
| Amgen INC. | $53.76 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $19.81 | 2020 | |
| Shire North American Group INC | $19.21 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $18.68 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manijeh Contractor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.